Ifetroban

Ifetroban (BMS-180291) is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research[1][2][3][4].

Product Specifications

CAS Number

[143443-90-7]

Product Name Alternative

BMS-180291

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cardiovascular Disease; Endocrinology; Cancer

Assay Protocol

https://www.medchemexpress.com/Ifetroban.html

Purity

99.65

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC(CCC(C=CC=C1)=C1C[C@@H]2[C@H](C3=NC(C(NCCCCC)=O)=CO3)[C@@H]4O[C@H]2CC4)=O

Molecular Formula

C25H32N2O5

Molecular Weight

440.53

Precautions

H302, H315, H319, H335

References & Citations

[1]Johnson RA, et al. Effect of ifetroban, a thromboxane A2 receptor antagonist, in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens. 1996 Feb;18 (2) :171-88.|[2]Schumacher WA, et al. Antiplatelet activity of the long-acting thromboxane receptor antagonist BMS 180,291 in monkeys. Prostaglandins. 1992 Nov;44 (5) :389-97.|[3]Werfel TA, et al. Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study. Mol Cancer Ther. 2020 Dec;19 (12) :2454-2464. |[4]Rosenfeld L, et al. Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist. Cardiovasc Drug Rev. 2001 Summer;19 (2) :97-115.